Camille L Bedrosian
CIK 1326969 · Chief Medical Officer · last filed 2026-09-01
Camille L Bedrosian is a Chief Medical Officer who has filed 51 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing shows the insider disposed of $1.9M of CRNX on Sep 1, 2026. Across all open-market trades the lifetime net is −$6.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.6M across reported positions. 20 SEC filings were submitted jointly with Ultragenyx Pharmaceutical Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$10.57M
5
51
-$6.51M
Filer Profile
60 LEVERONI COURT
NOVATO, CA 94949
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRNX | Director | 0 | $84.95 | $0 | $0 | 8 | 2026-09-01 |
| AMLX | Chief Medical Officer | 288,092 | $31.62 | $9.11M | -$473.8K | 11 | 2026-08-20 |
| RYTM | Director | 7,000 | $104.71 | $733.0K | $0 | 8 | 2025-06-26 |
| RARE | EVP and Chief Medical Officer | 50,601 | $14.30 | $723.6K | -$6.04M | 19 | 2023-03-03 |
| ARIAD PHARMACEUTICALS INC (ARIA) Delisted | VP, Chief Medical Officer | — | — | — | $0 | 1 | 2007-04-18 |
Recent Filings
51 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-01 | CRNX | Disp (D) | −22,225 | -$1.89M | EDGAR |
| 2026-08-20 | AMLX | Grant (A) | +22,807 | $0 | EDGAR |
| 2026-06-22 | CRNX | Grant (A) | +5,925 | $0 | EDGAR |
| 2026-03-09 | AMLX | Grant (A) | +95,990 | $0 | EDGAR |
| 2026-03-04 | RYTM | Notice (144) | −64,540 | -$5.85M | EDGAR |
| 2026-03-04 | AMLX | Sell (S) | −6,461 | -$94.2K | EDGAR |
| 2026-03-03 | RYTM | Notice (144) | −35,460 | -$3.21M | EDGAR |
| 2026-03-02 | AMLX | Notice (144) | −6,461 | -$94.2K | EDGAR |
| 2025-12-03 | AMLX | Sell (S) | −6,580 | -$94.4K | EDGAR |
| 2025-12-01 | AMLX | Notice (144) | −6,580 | -$94.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.